Humacyte, Inc.
HUMAHealthcare|Biotechnology|US
$0.45
+0.05 (+13.32%)
Tangible Book / Share
$0.13
Cash / Share
$0.34
Clinical Trials (15)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05908084 To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | End Stage Renal Disease (ESRD) | P3 | Active | 121 | RCT, Single-blind | Acellular Tissue Engineered Vessel (ATEV) |
| NCT07762794 Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting in Patients With Extremity Arterial Injury Requiring Urgent Repair | Vascular Injury, Arterial Injury | P4 | Not Yet Recruiting | 125 | Open-label | Acellular Tissue Engineered Vessel |
| NCT02644941 Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis | Renal Failure, End Stage Renal Disease | P3 | Completed | 355 | RCT, Open-label | Human Acellular Vessel (HAV) |
| NCT07762313 An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury. | Vascular Trauma, Arterial Injury | P3 | Not Yet Recruiting | 10 | Open-label | Acellular Tissue Engineered Vessel (Symvess) |
| NCT03005418 Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma | Trauma, Vascular System Injury | P2P3 | Completed | 72 | Open-label | Acellular Tissue Engineered Vessel (ATEV) |
| NCT03183245 Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis | Renal Failure, End Stage Renal Disease | P3 | Completed | 242 | RCT, Open-label | Human Acellular Vessel (HAV) |
| NCT02887859 Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD | Peripheral Artery Disease | P2 | Completed | 15 | Open-label | Human Acellular Vessel (HAV) |
| NCT04135417 Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for Dialysis | Renal Failure, End Stage Renal Disease | P2 | Completed | 30 | Open-label | HAV |
| NCT07730528 Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG) | Coronary Artery Disease | P2 | Not Yet Recruiting | 10 | Open-label | Humacyte Coronary Tissue Engineered Vessel (CTEV) |
| NCT01840956 Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease | End-stage Renal Disease, Kidney Failure, Chronic | P1 | Completed | 20 | Open-label | HAVG |
| NCT05873959 An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma | Trauma, Trauma Injury | Completed | 17 | — | HAV implantation | |
| NCT01744418 Evaluation of the Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With ESRD | End-stage Renal Disease, Kidney Failure, Chronic | N/A | Completed | 40 | Open-label | — |
| NCT01872208 Evaluation of the Safety and Efficacy of a Vascular Prosthesis as an Above-Knee Bypass Graft in Patients With PAD | Peripheral Arterial Disease, Peripheral Vascular Disease | N/A | Completed | 20 | Open-label | HAV implantation |
| NCT07141641 Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular Disease and Dialysis Access | Vascular Diseases, End Stage Renal Disease on Dialysis | TEMPORARILY_NOT_AVAILABLE | — | — | Acellular Tissue Engineered Vessel (ATEV) | |
| NCT03631056 Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular System Injuries | Vascular System Injuries | APPROVED_FOR_MARKETING | — | — | Acellular Tissue Engineered Vessel (ATEV) / Human Acellular Vessel (HAV) |